Notes in 06 Pulmonary

To Subscribe, use this Key

Status	Last Update	Fields
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryA relative contraindication to macro-aggregated albumin (MAA) is {{c1::severe pulmonary hypertension::disease}…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryRenal uptake can also be seen if free pertechnetate is present, but evaluation of the {{c1::head}} and {{c2::n…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryXenon-133 requires good patient cooperation as the patient must {{c1::breathe on a closed spirometer}} fo…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryExhaled {{c1::xenon-133::radiotracer}} must be carefully disposed of, either {{c2::exhausted to the atmosphere…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryXenon-133 must be administered in a {{c1::negative::negative/positive}} pressure room to prevent accidental le…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryXenon-133 is soluble in {{c1::fat}}, and it can accumulate in the {{c2::liver, particularly a fatty liver::org…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryAdvantages for using Tc-99m DTPA over Xenon:Ability to image in {{c1::multiple projections}} little requi…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonarySwallowed Tc-99m DTPA activity can be seen in the {{c1::esophagus}} and {{c2::stomach}}.
Published	05/01/2023	Nuclear and Molecular Imaging: Pulmonary{{c1::Pulmonary embolism}} is the leading cause of death in pregnancy in the developed world, and diagnosis mu…
Published	05/01/2023	Nuclear and Molecular Imaging: Pulmonary{{c1::Low-dose perfusion (Q)}} scan: Maternal breast dose {{c2::0.6}} mGy. Fetal dose {{c3::0.1–0.2}} mGy.
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryIn pregnancy, diagnostic accuracy for PE has been shown to be equivalent between {{c1::CTPA::modality}} and {{…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryThe primary advantage of CTPA is the demonstration of {{c1::an alternative diagnosis}} not seen on plain …
Published	05/01/2023	Nuclear and Molecular Imaging: Pulmonary{{c1::High}} probability for pulmonary embolism: RPO (right posterior oblique) perfusion images after 4.7 mCi …
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: {{c1::One::quantity}} large segmental mismatched perfusion defect denotes {{c2::intermediate}}…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: A {{c1::triple matched::type of}} defect in the {{c3::lower}} lung is considered an {{c2::intermedi…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: A {{c1::triple matched}} defect describes a defect on {{c2::perfusion::perfusion/ventilation}}…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: A {{c1::single large or moderate matched}} V/Q defect is {{c2::low}} probability of pulmonary …
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: Other low probability results are {{c1::absent perfusion}} of an entire lung, or more than {{c2::th…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: {{c1::Nonsegmental}} defects denote {{c2::very low}} probability.
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: The {{c1::stripe}} sign peripheral to a perfusion defect denotes {{c2::very low}} probability for p…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: The {{c1::stripe}} sign represents a thin line of MAA uptake between a {{c2::perfusion defect}…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: If the {{c1::perfusion::perfusion/ventilation}} scan is normal, the exam is normal and the {{c…
Published	05/01/2023	Nuclear and Molecular Imaging: Pulmonary{{c1::Xenon-133}} is an inhaled gas with a physical half-life of {{c2::5.3 days}}, which emits 81 ke…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryThe critcal organ for Xenon-133 is the {{c1::trachea}}.
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryThe biologic half-life for Xenon-133 is very short because the vast majority of the gas is {{c1::exh…
Published	05/01/2023	Nuclear and Molecular Imaging: Pulmonary{{c1::Xenon-133::radiotracer}} is imaged {{c2::posteriorly::anteriorly/posteriorly}} to avoid breast artifacts…
Published	05/01/2023	Nuclear and Molecular Imaging: Pulmonary{{c1::Wash-in/washout}} imaging with Xenon-133 can be performed to evaluate for {{c2::air trapping}}…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryV/Q scan:Maternal breast dose: {{c1::<1.5}} mGy.Fetal dose {{c2::0.5–1.1}} mGy
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryCT pulmonary angiogram (CTPA): Maternal breast dose {{c1::10–70}} mGyACR mammography guideline:…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryTypically {{c1::3–5 millicurie (mCi)::amount}} Tc-99m MAA are administered intravenously, comprising…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryTc-99m MAA particles begin to break down in approximately {{c4::30}} minutes.
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryTc-99m MAA study:Free pertechnetate uptake in {{c1::thyroid }}Right-to-left shunt: contrast uptake in {{c…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryTc-99m DTPA is a technetium-labeled aerosol and does not allow for {{c1::dynamic wash-in/washout}} i…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryOnce Tc-99m DTPA is inhaled, the particles remain in place for approximately {{c1::45–60}} minutes (…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II:{{c1::Two or more large mismatched}} segmental defects without associated radiographi…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryPIOPED II: solitary triple-matched defect:mid-upper lung → {{c1::very low}} probability&nb…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryCriteria for nuclear medicine perfusion scan in a pregnant patient:{{c1::normal}} chest radiographno history o…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryIn clinical practice, what is the preferred study for suspected PE in a pregnant patient?{{c1::CTPA}}
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryThe dose of Tc-99m MAA can be halved to approximately 100,000 particles in what kind of patients?In …
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryIn most pregnancy PE cases, only {{c1::perfusion}} scan is necessary and {{c1::ventilation}} sc…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryClumping of {{c1::macro-aggregated albumin (MAA)}} can be seen when it is inadvertently drawn b…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryA right-to-left shunt causes immediate {{c1::renal}} and {{c1::brain}} uptake after intravenous Tc-9…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryWhat study can be used to quantify shunt fraction in patients with a right-to-left shunt?{{c1::Tc-99m MAA stud…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryTc-99m MAA is a particulate radiopharmaceutical that lodges in the {{c1::pulmonary capillary bed}} and ca…
Published	05/01/2023	Nuclear and Molecular Imaging: PulmonaryTc-99m-MAA particles are between {{c1::10-30}} μm in size.
Status	Last Update	Fields